請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49825
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺(Ji-Wang Chern) | |
dc.contributor.author | Kuang-Jui Wang | en |
dc.contributor.author | 王光瑞 | zh_TW |
dc.date.accessioned | 2021-06-15T11:50:52Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-11 | |
dc.identifier.citation | 1. Alifieris C.; Trafalis D. T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 2015, 152, 63–82.
2. Scott C. B.; Scarantino C.; Urtasun R.; Movsas B.; Jones C. U.; Simpson J. R.; Fischbach A. J.; Curran W. J. Jr. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40, 51-5. 3. Stupp R.; Mason W. P.; van den Bent M. J.; Weller M.; Fisher B.; Taphoorn M. J.; Belanger K.; Brandes A. A.; Marosi C.; Bogdahn U.; Curschmann J.; Janzer R. C.; Ludwin S. K.; Gorlia T.; Allgeier A.; Lacombe D.; Cairncross J. G.; Eisenhauer E.; Mirimanoff R. O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–96. 4. Chen C.; Xu T.; Lu Y.; Chen J.; Wu S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur. J. Neurol. 2013, 20, 223–30. 5. Kang J. H.; Adamson C. Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opin. Investig. Drugs. 2015, 24, 1361–79. 6. a) Batchelor T.; Curry T. W. Jr. Clinical manifestations and initial surgical approach to patients with high-grade gliomas. b) Batchelor T.; Supko G. J. Experimental treatment approaches for high-grade gliomas. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011. (cited: 06/25/2016). 7. Tanaka S.; Louis D. N.; Curry W.T.; Batchelor T.T.; Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. 2013, 10, 14–26. 8. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008, 455, 1061–8. 9. Rich J. N.; Reardon D. A.; Peery T.; Dowell J. M.; Quinn J. A.; Penne K. L.; Wikstrand C. J.; Van Duyn L. B.; Dancey J. E.; McLendon R. E.; Kao J. C.; Stenzel T. T.; Ahmed Rasheed B. K.; Tourt-Uhlig S. E.; Herndon J. E. 2nd.; Vredenburgh J. J.; Sampson J. H.; Friedman A. H.; Bigner D. D.; Friedman H. S. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 2004, 22, 133–42. 10. van den Bent M. J.; Brandes A. A.; Rampling R.; Kouwenhoven M. C.; Kros J. M.; Carpentier A. F.; Clement P. M.; Frenay M.; Campone M.; Baurain J. F.; Armand J. P.; Taphoorn M. J.; Tosoni A.; Kletzl H.; Klughammer B.; Lacombe D.; Gorlia T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 2009, 27, 1268–74. 11. Reardon D. A.; Nabors L. B.; Mason W. P.; Perry J. R.; Shapiro W.; Kavan P.; Mathieu D.; Phuphanich S.; Cseh A.; Fu Y.; Cong J.; Wind S.; Eisenstat D. D.; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro. Oncol. 2015, 17, 430–9. 12. Kang J. H.; Adamson C. Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opin. Investig. Drugs. 2015, 24, 1361–79. 13. Greenall S. A.; Donoghue J. F.; Gottardo N. G.; Johns T. G.; Adams T. E. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo. Oncogene. 2015, 34, 1658–66. 14. Batchelor T. T.; Duda D. G.; di Tomaso E.; Ancukiewicz M.; Plotkin S. R.; Gerstner E.; Eichler A. F.; Drappatz J.; Hochberg F. H.; Benner T.; Louis D. N.; Cohen K. S.; Chea H.; Exarhopoulos A.; Loeffler J. S.; Moses M. A.; Ivy P.; Sorensen A. G.; Wen P. Y.; Jain R. K. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 2010, 28, 2817–23. 15. Wang T.; Agarwal S.; Elmquist W. F. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J. Pharmacol. Exp. Ther. 2012, 341, 386-95. 16. Neyns B.; Sadones J.; Chaskis C.; Dujardin M.; Everaert H.; Lv S.; Duerinck J.; Tynninen O.; Nupponen N.; Michotte A.; De Greve J. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol. 2011, 103, 491–501. 17. Pan E.; Yu D.; Yue B.; Potthast L.; Chowdhary S.; Smith P.; Chamberlain M. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J. Neurooncol. 2012, 110, 111–8. 18. Reardon D. A.; Dresemann G.; Taillibert S.; Campone M.; van den Bent M.; Clement P.; Blomquist E.; Gordower L.; Schultz H.; Raizer J.; Hau P.; Easaw J.; Gil M.; Tonn J.; Gijtenbeek A.; Schlegel U.; Bergstrom P.; Green S.; Weir A.; Nikolova Z. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer. 2009, 101, 1995–2004. 19. Razis E.; Selviaridis P.; Labropoulos S.; Norris J. L.; Zhu M. J.; Song D. D.; Kalebic T.; Torrens M.; Kalogera-Fountzila A.; Karkavelas G.; Karanastasi S.; Fletcher J. A.; Fountzilas G. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin. Cancer Res. 2009, 15, 6258–66. 20. Dresemann G.; Weller M.; Rosenthal M. A.; Wedding U.; Wagner W.; Engel E.; Heinrich B.; Mayer-Steinacker R.; Karup-Hansen A.; Fluge O.; Nowak A.; Mehdorn M.; Schleyer E.; Krex D.; Olver I. N.; Steinbach J. P.; Hosius C.; Sieder C.; Sorenson G.; Parker R.; Nikolova Z. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 2010, 96, 393–402. 21. Reardon D. A.; Desjardins A.; Vredenburgh J. J.; Gururangan S.; Friedman A. H.; Herndon J. E. 2nd.; Marcello J.; Norfleet J. A.; McLendon R. E.; Sampson J. H.; Friedman H. S. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 2010, 96, 219–30. 22. Sarkaria J. N.; Galanis E.; Wu W.; Dietz A. B.; Kaufmann T. J.; Gustafson M. P.; Brown P. D.; Uhm J. H.; Rao R. D.; Doyle L.; Giannini C.; Jaeckle K. A.; Buckner J. C. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin. Cancer Res. 2010, 16, 5573–80. 23. Galanis E.; Buckner J. C.; Maurer M. J.; Kreisberg J. I.; Ballman K.; Boni J.; Peralba J. M.; Jenkins R. B.; Dakhil S. R.; Morton R. F.; Jaeckle K. A.; Scheithauer B. W.; Dancey J.; Hidalgo M.; Walsh D. J.; North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23, 5294–304. 24. Jo M. Y.; Kim Y. G.; Kim Y.; Lee S. J.; Kim M. H.; Joo K. M.; Kim H. H.; Nam D. H. Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms. Mol. Med. Rep. 2012, 6, 88–92. 25. Kreisl T. N.; McNeill K. A.; Sul J.; Iwamoto F. M.; Shih J.; Fine H. A. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro. Oncol. 2012, 14, 1519–26. 26. Galanis E.; Jaeckle K. A.; Maurer M. J.; Reid J. M.; Ames M. M.; Hardwick J. S.; Reilly J. F.; Loboda A.; Nebozhyn M.; Fantin V. R.; Richon V. M.; Scheithauer B.; Giannini C.; Flynn P. J.; Moore D. F. Jr.; Zwiebel J.; Buckner J. C. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 2009, 27, 2052–8. 27. Drappatz J.; Lee E. Q.; Hammond S.; Grimm S. A.; Norden A. D.; Beroukhim R.; Gerard M.; Schiff D.; Chi A. S.; Batchelor T. T.; Doherty L. M.; Ciampa A. S.; Lafrankie D. C.; Ruland S.; Snodgrass S. M.; Raizer J. J.; Wen P. Y. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J. Neurooncol. 2012, 107, 133–8. 28. Iwamoto F. M.; Lamborn K. R.; Kuhn J. G.; Wen P. Y.; Yung W. K.; Gilbert M. R.; Chang S. M.; Lieberman F. S.; Prados M. D.; Fine H. A. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro. Oncol. 2011, 13, 509–16. 29. Weller M.; Gorlia T.; Cairncross J. G.; van den Bent M. J.; Mason W.; Belanger K.; Brandes A. A.; Bogdahn U.; Macdonald D. R.; Forsyth P.; Rossetti A. O.; Lacombe D.; Mirimanoff R. O.; Vecht C. J.; Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011, 77, 1156–64. 30. Oberndorfer S.; Piribauer M.; Marosi C.; Lahrmann H.; Hitzenberger P.; Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J. Neurooncol. 2005, 72, 255–60. 31. Weichert W.; Röske A.; Gekeler V.; Beckers T.; Ebert M. P.; Pross M.; Dietel M.; Denkert C.; Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9, 139–48. 32. Weichert W.; Röske A.; Niesporek S.; Noske A.; Buckendahl A. C.; Dietel M.; Gekeler V.; Boehm M.; Beckers T.; Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14, 1669–77. 33. Haberland M.; Montgomery R. L.; Olson E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32–42. 34. Ma X.; Ezzeldin H. H.; Diasio R. B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009, 69, 1911–34. 35. Marks P. A.; Xu W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell Biochem. 2009, 107, 600–8. 36. Marks P. A. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta. 2010, 1799, 717–25. 37. West A.C.; Johnstone R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 2014, 124, 30–9. 38. Mottamal M.; Zheng S.; Huang T. L.; Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015, 20, 3898–41. 39. Witt O.; Deubzer H. E.; Milde T.; Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8–21. 40. Kalin J. H.; Bergman J. A. Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J. Med. Chem. 2013, 56, 6297–313. 41. Zhang y.; Kwon S.; Yamaguchi T.; Cubizolles F.; Rousseaux S.; Kneissel M.; Cao C.; Li N.; Cheng H. L.; Chua K.; Lombard D.; Mizeracki A.; Matthias G.; Alt W. F.; Khochbin S.; Matthias P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell Biol. 2008, 28, 1688–701. 42. Micromedex® 2.0 (electronic version). Thomson Reuters (Healthcare) Inc., Greenwood Village, Colorado, USA. Available at: http://www.thomsonhc.com (cited: 07/08/2016). 43. Seidel C.; Schnekenburger M.; Dicato M.; Diederich M. Histone deacetylase 6 in health and disease. Epigenomics. 2015, 7, 103–18. 44. Kovacs J. J.; Murphy P. J.; Gaillard S.; Zhao X.; Wu J. T.; Nicchitta C. V.; Yoshida M.; Toft D. O.; Pratt W. B.; Yao T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell. 2005, 18, 601–7. 45. Zhang Y.; Kwon S.; Yamaguchi T.; Cubizolles F.; Rousseaux S.; Kneissel M.; Cao C.; Li N.; Cheng H. L.; Chua K.; Lombard D.; Mizeracki A.; Matthias G.; Alt F. W.; Khochbin S.; Matthias P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell Biol. 2008, 28, 1688-701. 46. de Ruijter A. J.; van Gennip A. H.; Caron H. N.; Kemp S.; van Kuilenburg A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737–49. 47. Li S.; Liu X.; Chen X.; Zhang L.; Wang X. Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling. Tumour Biol. 2015, 36, 9661-5. 48. Wang Z.; Hu P.; Tang F.; Lian H.; Chen X,; Zhang Y.; He X.; Liu W.; Xie C. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. Cancer Lett. 2016, 379,134–42. 49. Butler K. V.; Kalin J.; Brochier C.; Vistoli G.; Langley B.; Kozikowski A. P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem Soc. 2010, 132, 10842–6. 50. Kamal A.; Bolla N. R.; Srikanth P. S.; Srivastava A. K. Naphthalimide derivatives with therapeutic characteristics: a patent review. Expert Opin. Ther. Pat. 2013, 23, 299–317. 51. Su G. H.; Sohn T. A.; Ryu B.; Kern S. E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 2000, 60, 3137–42. 52. Kuribayashi T.; Ohara M.; Sora S.; Kubota N. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int. J. Mol. Med. 2010, 25, 25–9. 53. Abaza M. S.; Bahman A. M.; Al-Attiyah R. J.; Kollamparambil A. M. Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. Tumour Biol. 2012, 33, 1951–72. 54. Kishigami S.; Nguyen V. T.; Wakayama S.; Wakayama T. Chapter 11 Enhancing SCNT with Chromatin Remodeling Agents. In Principles of Cloning, 2nd ed.; Wilmut I.; Jaenisch R.; Gurdon J.; Lanza R.; West M.; Campbell K.; Cibelli J. Eds.; Elsevir: Amsterdam, 2014, 137–148. 55. Sharma V.; Koul N.; Joseph C.; Dixit D.; Ghosh S.; Sen E. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J. Cell. Mol. Med. 2010, 14, 2151–61. 56. Keen J. C.; Yan L.; Mack K. M.; Pettit C.; Smith D.; Sharma D.; Davidson N. E. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res. Treat. 2003, 81, 177–86. 57. Yu C. W.; Chang P. T.; Hsin L. W.; Chern J. W. Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 2013, 56, 6775–91. 58. Fleming C. L.; Ashton T. D.; Nowell C.; Devlin M.; Natoli A.; Schreuders J.; Pfeffer F. M. A fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging. Chem. Commun. 2015, 51, 7827–30. 59. Fang C. L.; Zhou J.; Liu X. J.; Cao Z. H.; Shangguan D. H. Mercury(II)-mediated formation of imide-Hg-imide complexes. Dalton Trans. 2011, 40, 899–903. 60. Yu C. W.; Chen G. S.; Huang C. W.; Chern J. W. Efficient microwave-assisted Pd-catalyzed hydroxylation of aryl chlorides in the presence of carbonate. Org. Lett. 2012, 14, 3688–91. 61. Georgiev N. I.; Bojinov V. B. The design and synthesis of a novel 1,8-naphthalimide PAMAM light-harvesting dendron with fluorescence “off-on” switching core. Dyes and Pigments. 2010, 84, 249–56. 62. Suna W.; Lia W.; Lia J.; Zhangb J.; Dua L.; Li M. Naphthalimide-basedfluorescent off/on probes for the detection of thiols. Tetrahedron. 2012, 68, 5363–7. 63. Wu A.; Xu Y.; Qian X. Novel naphthalimide–indomethacin hybrids as potential antitumoragents: effects of linkers on hypoxic/oxic cytotoxicityand apoptosis-inducing activity. Monatsh Chem. 2010, 141, 893–9. 64. MacGregor K. A.; Robertson M. J.; Young K. A.; von Kleist L.; Stahlschmidt W.; Whiting A.; Chau N.; Robinson P. J.; Haucke V.; McCluskey A. Development of 1,8-naphthalimides as clathrin inhibitors. J. Med. Chem. 2014, 57, 131–43. 65. He H.; Mortellaro M. A.; Leiner M. J.; Fraatz R. J.; Tusa J. K. A fluorescent sensor with high selectivity and sensitivity for potassium in water. J. Am. Chem. Soc. 2003, 125, 1468–9. 66. Harps?e N. G.; Andersen L. P.; Gögenur I.; Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur. J. Clin. Pharmacol. 2015, 71, 901–9. 67. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 1997, 336, 186–95. 68. Reppert S. M.; Perlow M. J.; Tamarkin L.; Klein D. C. A diurnal melatonin rhythm in primate cerebrospinal fluid. Endocrinology. 1979, 104, 295–301. 69. a) Goldstein A. C. Jet lag.; b) Wurtman R. Physiology and available preparations of melatonin. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011. (cited: 06/25/2016). 70. Kinker G. S.; Oba-Shinjo S. M.; Carvalho-Sousa C. E.; Muxel S. M.; Marie S. K.; Markus R. P.; Fernandes P. A. Melatonergic system-based two-gene index is prognostic in human gliomas. J. Pineal Res. 2016, 60, 84–94. 71. Martín V.; Herrera F.; Carrera-Gonzalez P.; García-Santos G.; Antolín I.; Rodriguez-Blanco J.; Rodriguez C. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res. 2006, 66, 1081–8. 72. Wang J.; Hao H.; Yao L.; Zhang X.; Zhao S.; Ling E. A.; Hao A.; Li G. Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J. Pineal Res. 2012, 53, 180–7. 73. Martín V.; Sanchez-Sanchez A. M.; Puente-Moncada N.; Gomez-Lobo M,.; Alvarez-Vega M. A.; Antolín I.; Rodriguez C. Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. J. Pineal Res. 2014, 57, 308–16. 74. Martín V.; Sanchez-Sanchez A. M.; Herrera F.; Gomez-Manzano C.; Fueyo J.; Alvarez-Vega M. A.; Antolín I.; Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br. J. Cancer. 2013, 108, 2005–12. 75. Faust R.; Garratt P. J.; Jones R.; Yeh L. K.; Tsotinis A.; Panoussopoulou M.; Calogeropoulou T.; Teh M. T.; Sugden D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a] indoles. J. Med. Chem. 2000, 43, 1050–61. 76. Matoušek V.; Pietrasiak E.; Schwenk R.; Togni A. One-pot synthesis of hypervalent iodine reagents for electrophilic trifluoromethylation. J. Org. Chem. 2013, 78, 6763–8. 77. Shimizua R.; Egamia H.; Nagia T.; Chaea J.; Hamashimaa Y.; Sodeoka M. Direct C2-trifluoromethylation of indole derivatives catalyzed by copper acetate. Tetrahedron Lett. 2010, 51, 5947–9. 78. Oprea-Ilies G.; Haus E.; Sackett-Lundeen L.; Liu Y.; McLendon L.; Busch R.; Adams A.; Cohen C. Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. Breast Cancer Res. Treat. 2013, 137, 677–87. 79. Hill S. M.; Frasch T.; Xiang S.; Yuan L.; Duplessis T.; Mao L. Molecular mechanisms of melatonin anticancer effects. Integr. Cancer Ther. 2009, 8, 337–46. 80. DeMuro R. L.; Nafziger A. N.; Blask D. E.; Menhinick A. M.; Bertino J. S. Jr. The absolute bioavailability of oral melatonin. J. Clin. Pharmacol. 2000, 40, 781–4. 81. Ma X.; Idle J. R.; Krausz K. W.; Gonzalez F. J. Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos. 2005, 33, 489–94. 82. Verma M.; Luxamia V.; Paul K. Synthesis, in vitro evaluation and DNA interaction studies of N-allyl naphthalimide analogues as anticancer agents. RSC Adv. 2015, 5, 41803–13. 83. Reiter R. J.; Tan D. X.; Osuna C.; Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci. 2000, 7, 444-58. 84. Hardeland R.; Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 2012, 12, 189-216. 85. Grayshan P. H.; Kadhim A. M.; Perters A. T. Heterocyclic derivalives of naphthalene-1,8-dicar boxylie anhydride. Part III. Benzo[k,l] thioxanthene-3,4- dicarboximides. J. Heterocyclic Chem. 1974, 11, 33-38. 86. Kilpin K. J.; Clavel C. M.; Edafe F., Dyson P. J. Naphthalimide-Tagged Ruthenium–Arene Anticancer Complexes: Combining Coordination with Intercalation. Organometallics, 2012, 31, 7031–39. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49825 | - |
dc.description.abstract | 本論文主旨為發展第六亞型組蛋白去乙醯酶抑制劑作為治療惡性腦癌―多形性膠質母細胞瘤可行性之研究。
三環結構的萘二甲醯亞胺(naphthalimide)是常見的螢光發光基團。本論文以此作為核心基團,以對甲基苯連結異羥肟酸(hydroxamate),在對位及間位做取代基修飾,共合成出七個目標化合物,探討結構活性關係。其中化合物13d (HDAC6 IC50 = 0.1 nM, HDAC1 IC50 = 108 nM)的HDAC6抑制活性低於nM,且對HDAC1選擇性達到1080倍,而腦癌細胞U87MG的細胞毒性達0.92 μM。在構效關係上,對位氧取代或氮取代基團可以增加活性;而間位的取代則會失去活性。 另一部分,由於褪黑激素(melatonin)具有進入血腦障壁及低毒性的特色,因此以褪黑激素為主結構設計成HDAC6 抑制劑,並合成出兩個化合物作模式設計的可能性。其中化合物16a的HDAC6 IC50 5.5 nM 且U87MG的細胞毒性也達到0.97 μM。藥動研究發現16a和16b會快速吸收代謝。在褪黑激素的2號位做三氟甲基取代會使口服吸收率降低。化合物16a的腦血濃度比會隨著時間而增加,在1.5小時達到3.77倍。 總結本論文提供兩類化合物,作為潛力抗多形性膠質母細胞瘤藥物研究的可行性,其藥動學仍有待改善。 | zh_TW |
dc.description.abstract | The aim of this thesis is to develop histone deacetylase 6 (HDAC6) selective inhibitors for the potential glioblastoma multiforme treatment.
The tricyclic naphthalimide is a well-known pro-fluorophore. To design and synthesize HDAC6 inhibitors, we employed naphthalimide as the core structure and connected with hydroxamate group through p-toyl linker, and seven target compounds were synthesized for SAR study. Compound 13d (HDAC6 IC50 = 0.1 nM, HDAC1 IC50 = 108 nM) showed sub-nM inhibition against HDAC6 and 1080 times of selectivity against HDAC6 over HDAC1, and U87MG IC50 0.92 μM. From SAR studies, O-substitution or N-substitution at para position provided better activities. However, substitutions at meta position lost inhibition against HDAC and cancer cell lines. Second part, melatonin was also selected as a core structure for HDAC6 inhibitor design, due to its blood-brain barrier penetrating and non-toxic properties, and two derivatives were synthesized. Compound 16a demonstrated IC50 0.97 μM against glioblastoma cell line with HDAC6 IC50 5.5 nM. Both 16a and 16b has a rapid absorption and metabolic properties. Trifluoromethyl at melatonin C2 position will lead to poor bioavailability. In vivo Kp of 16a increases with time, and Kp at 1.5 hr is 3.77. To sum up, two scaffolds of HDAC6 inhibitors were developed for the potential therapeutic agents against glioblastoma in this study. Further studies on the improvement of pharmacokinetic properties are needed. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:50:52Z (GMT). No. of bitstreams: 1 ntu-105-R03423002-1.pdf: 2826251 bytes, checksum: 723af1ff5467358386849c681cb1e99f (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 中文摘要 1
Abstract 2 Chapter 1 Introduction 7 1.1. Glioblastoma multiforme 7 1.2. Novel treatment for glioblastoma multiforme 8 1.3. Histone deacetylase (HDAC) 9 Chapter 2 Design and Synthesis of Naphthalimide Derivatives as HDAC6 Selective Inhibitors 13 2.1. Introduction and rational design 13 2.2. Naphthalimide derivatives 14 2.3. Results and Discussion – Chemistry 15 2.4. Results and Discussion – Biological activity 17 2.5. Results and Discussion – Photophysical properties 20 2.6. Experimental Section 21 Chapter 3 Design and Synthesis of Melatonin Derivatives as HDAC6 Selective Inhibitors 42 3.1. Introduction and rational design 42 3.2. Results and Discussion – Chemistry 43 3.3. Results and Discussion – Biological activity 44 3.4. Results and Discussion – Pharmacokinetic studies 46 3.5. Experimental Section 48 Chapter 4 Conclusion and Discussion 55 References 56 Appendix for Spectra of 1H NMR and 13C NMR 63 | |
dc.language.iso | en | |
dc.title | 第六亞型組蛋白去乙醯酶抑制劑作為潛能抗多形性膠質母細胞瘤之設計與合成 | zh_TW |
dc.title | Design and Synthesis of HDAC6 Selective Inhibitors as
Potential Agent Against Glioblastoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 忻凌偉(Ling-Wei Hsin),梁碧惠(Pi-Hui Ling),王光昭(Kuang-Chao Wang) | |
dc.subject.keyword | 第六亞型組蛋白去乙醯?抑制劑,多形性膠質母細胞瘤,?二甲醯亞胺,褪黑激素, | zh_TW |
dc.subject.keyword | histone deacetylase 6,HDAC6,glioblastoma multiforme,GBM,naphthalimide,melatonin, | en |
dc.relation.page | 71 | |
dc.identifier.doi | 10.6342/NTU201602295 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 2.76 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。